 |
Amgen drug cuts cancer bone problem riskA third pivotal trial of Amgen's denosumab found that it delayed by 21 per cent the risk of fractures and other bone complications in men with advanced prostate cancer compared with current therapy. Amgen filed last month for US Food and D More… |
Friday 17 May 2024
